[Management of immune-related adverse events during treatment with immune checkpoint inhibitors].
Immunotherapy with anti-CTLA-4 and anti-PD-1 monoclonal antibodies is a breakthrough in the treatment of advanced cancer. The progressively broader indications of such drugs highlights the need of developing algorithms for the management of immune-related toxicities, as some adverse events may cause sequelae and even death if not managed effectively. Thanks to the collaboration of different specialist from the Gustave Roussy Institute in Paris, guidelines for the management of toxicities during treatment with immune checkpoint inhibitors were recently published on the journal Annals of Oncology. The purpose of this article is to review and discuss such guidelines.